Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

June 6, 2022

The TOGETHER Trial Journey: Interview with Ofir Harari

The award-winning TOGETHER Trial was designed with the vision of ensuring that COVID-19 therapies are both effective...

Read article

May 31, 2022

What it means to be a lead analyst on a Global COVID-19 Trial

The TOGETHER Trial for COVID-19 therapies, designed by clinical trial specialists at Cytel won the Society for Clinical...

Read article

May 17, 2022

Society of Clinical Trials names TOGETHER "Trial of the Year"

Early in the pandemic, it became clear that many of the COVID-19 therapies being tested in wealthier nations, were not...

Read article

May 4, 2021

New Publication on Adaptive Platform Trials

As healthcare systems across the world, continue to grapple with the pressures of COVID-19, Cytel advances yet another...

Read article

December 2, 2020

Program and Portfolio Optimization: A New Paradigm

Significant advances have been made to enhance the efficiency of clinical trial designs. However, the traditional...

Read article

October 9, 2020

Cyrus Mehta on Increasing the Power of Platform Trials

Even before the era of COVID-19, significant attention was channeled to the overwhelming potential of adaptive MAMS...

Read article

September 28, 2020

Advantages of platform designs for investigating COVID-19 therapies

Cytel has recently designed and implemented the TOGETHER Trials, funded by the Bill & Melinda Gates Foundation to...

Read article

September 21, 2020

Novel Adaptive Platform Trial for COVID-19 Therapies

Cytel has designed and implemented a novel adaptive platform trial for early stage COVID-19. The severity of the...

Read article

June 24, 2020

Webinar - Practical Model-based Approaches for Phase I Oncology Trials

Last week, Cytel conducted its third webinar in the new introductory webinar series on Complex Innovative Trial...

Read article

June 15, 2020

Significance of Bayesian Model-Based Approaches in Oncology Trials: An Interview with Dr. Satrajit Roychoudhury

Cytel conducted a webinar with Dr. Satrajit Roychoudhury, Senior Director, Statistical Research and Data Science...

Read article

June 1, 2020

Webinar Replay: Innovative Drug Development at a Glance

In a recent interview with Cytel, Zoran Antonijevic, longstanding chair and leader of the DIA Adaptive Design...

Read article

May 28, 2020

Implications for the Future of Drug Development in Emerging Economies

On May 7, Cytel and Certara conducted a virtual panel discussion on new opportunities and implications for the future...

Read article

May 18, 2020

Interview with Zoran Antonijevic on Adaptive Design Methods

In this blog, we speak with Zoran Antonijevic, longstanding chair and leader of the DIA Adaptive Design Scientific...

Read article

May 7, 2020

COVID-19: Trials, Designs and Tools for Promising Results - A Virtual Panel Discussion

An extraordinary amount of global research is underway as the COVID-19 pandemic continues to evolve and spread...

Read article

Therapeutics Development Team

Software

Innovative Trial Design

RWE

HEOR

Biometrics Implementation

Functional Service Provision

CDI

Events

Newsroom

Resources

Perspectives on Enquiry & Evidence

Aligning Clinical Trial Design with Investment Priorities

Subscribe to our weekly newsletter

Subscribe to our weekly newsletter